The Awakening of Consciousness Conference with Paul Karasik
Paul Karasik discusses The Psychedelic Institute's aspirations with the launch of the Awakening of Consciousness Conference
Similar Posts
![HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market? [ +Horizons ETF UPDATE]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-85-600x338.jpeg)
HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market? [ +Horizons ETF UPDATE]
Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. This segment is entitled “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more.
In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.
1. The Effects of Treating Depression with Psilocybin
2. Taking Psychedelics in a Ritual Setting
3. Microdosing study
After covering the pertinent aspects of these studies, we’ll take a look at Americans’ ability to buy Horizons’ ETF and finally we’ll give you some updates on some decriminalization efforts.
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedel
…
Timestamps:
0:00 – Intro
1:24 – Effects of Treating Depression with Psilocybin
4:03 – Effects of Taking Psychedelics in A Ritual Setting
7:23 – Exploring the relationship between microdosing, personality & emotional insight
9:36 – Americans May be able to invest in Horizon’s ETF
11:42 – Progress on California’s bill that would LEGALIZE Possession of Psychedelics
12:57 – Massachusetts Approves Psychedelics Decimalization
General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #psychedelics #shroomboom
Cathie Wood of Ark Invest Comments on Psychedelic Stocks like MindMed “We DON’T Invest In Binaries”
Will Ark Invest (ARKK) and Cathie Wood invest in MindMed ( MMED / MMEDF/ MMQ) or other Psychedelic Stocks? In this episode, Cathie Wood talks to Kevin O’Leary about the potential for psychedelic stocks and MindMed.
Kevin O’Leary is a BIG bull in MindMed, but what does Cathie Wood think? Will Ark invest in MindMed? Well, no. She is clear that Ark does not invest in binary outcomes, which MMED / MMEDF cleary is.
Having said this, the door may be left open for the future, as ARKK invests in Healthcare companies using artifical intellegence, exactly what MindMed’s Albert division is working on. Also, once clinical trial results come in, MindMed will no longer be a binary choice. SO anything is possible.
I hope this little impromptu episode added some life and joy to your live and that you guys found some value in this.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedNews #PsychedelicStocks
‘Right To Try Laws’ and Legal Access to Psilocybin Therapy with Dr. Jonathan Fields
Petitioning the DEA to respect the ‘Right to Try Laws’ which empower terminally ill patients to legally access psilocybin therapy.
Interview With Josh Bartch, Mydecine Innovations Group
Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founder & CEO, of Mydecine Innovations Group, Josh Bartch.
Doug Drysdale On How CYB-003 Is Better Than Psilocybin
In this episode, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN). In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues.
Atai Life Sciences IPOing TOMORROW ( Is Atai a BUY?)
ATAI IPOS TOMORROW! It’s finally happening! This Friday, on June 18th, 2021, the company I’ve been talking about for a while now, Atai Life Sciences, is set to IPO on the NASDAQ stock exchange, under ticker symbol “atai”.
This will automatically make Atai a runner for the title of the most advanced public psychedelic medicines company on the market.
So in this episode, we’ll discuss several things:
1. The details of the IPO
2. We’ll take a look at their financials
3. Look at Atai Life Sciences’ investment thesis
4. What I will be doing
Enjoy the episode!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Website: https://thepsychedelicinvestor.com/
editing: @themyaholy
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
https://www.atai.life/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Atai #AtaiLifeSciences #AtaiIPO